FOR THE SECOND YEAR IN A ROW, a student group of aspiring attorneys from Chicago’s Legal Prep Charter Academy took first place in an annual mock trial competition held at the specialized high school...
By: Jeffrey D. Mamorsky , COHEN & BUCKMANN, P.C. THIS VIDEO SERIES CELEBRATES THE ENACTMENT of the Employee Retirement Income Security Act (ERISA), signed by President Gerald Ford on September 2...
By: Kirk A. Sigmon , BANNER WITCOFF THIS CHECKLIST OUTLINES KEY CONSIDERATIONS THAT ATTORNEYS should review when advising whether and how to copyright artificial intelligence (AI) and machine learning...
Review this exciting guide to some of the recent content additions to Practical Guidance, designed to help you find the tools and insights you need to work more efficiently and effectively. Practical Guidance...
By: Erin Hanson , Arlene Arin Hahn , Sahra Nizipli , and Jordan Hill , WHITE & CASE LLP THIS ARTICLE SUMMARIZES VARIOUS INTELLECTUAL PROPERTY AND TECHNOLOGY (IP/IT) PROVISIONS, including sample definitions...
Copyright © 2024 LexisNexis and/or its Licensors.
By: Matthew D. Jenkins, Hunton Andrews Kurth LLP
This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response to the COVID-19 pandemic: (1) Medicare’s Advance Payment Program, (2) the Provider Relief Fund, and (3) the Paycheck Protection Program.
When you advise a healthcare company that receives federal funds about its compliance obligations, a basic understanding of the FCA is essential.
The FCA imposes civil penalties on persons who knowingly or with reckless disregard: CLICK HERE TO READ THE FULL ARTICLE IF YOU ARE A PRACTICAL GUIDANCE SUBSCRIBER